Home > Drugs A – Z > Calcium Acetate (By mouth)

Calcium Acetate (By mouth)

Reduces the amount of phosphorus in the blood.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Calcium acetate is used to treat hyperphosphatemia (too much phosphate in the blood) in patients with end stage kidney disease who are on dialysis. Calcium acetate works by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed. This medicine is available only with your doctor's prescription… Read more
Brand names include
Calphron, Eliphos, PhosLo, Phoslyra
Drug classes About this
Calcium Supplement, Phosphate Binder

What works? Research summarized

Evidence reviews

Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness [Internet]

A 2009 CADTH rapid review of the clinical effectiveness of sevelamer hydrochloride (HCL) for the treatment of chronic kidney disease (CKD) found that sevelamer HCL appeared to be as effective as calcium-based phosphate binders in the management of hyperphosphatemia in CKD patients on dialysis without inducing hypercalcemia. While there was evidence to suggest that sevelamer HCL may slow down the progression of vascular calcification, there was no evidence on its impact on mortality outcomes, and the evidence on its effectiveness on aortic calcification was inconsistent. The report concluded that the published literature at the time did not appear to support the routine use of sevelamer HCL in patients on dialysis.

Colestilan -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report is to assess the added benefit of colestilan for the treatment of hyperphosphataemia in adult patients with chronic kidney disease receiving haemodialysis or peritoneal dialysis (hereinafter referred to as CKD 5D). According to the Federal Joint Committee (G-BA)'s specification, 2 subindications are differentiated and the following appropriate comparator therapies (ACTs) are used for them:

Hyperphosphataemia in Chronic Kidney Disease: Management of Hyperphosphataemia in Patients with Stage 4 or 5 Chronic Kidney Disease

Chronic kidney disease (CKD) describes abnormal kidney function and/or structure. It is common and often exists together with other conditions, such as cardiovascular disease and diabetes.

See all (6)

Summaries for consumers

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients

People with chronic kidney disease (CKD) develop impaired excretion of the dietary phosphorus. This results in a condition known as mineral and bone disorder in chronic kidney disease (CKD‐MBD). CKD‐MBD is characterized by high bone turnover, increased musculoskeletal morbidity including bone pain and muscle weakness, and vascular calcification which may contribute to the high incidence of cardiovascular disease and associated deaths. Several agents such as phosphate binders, vitamin D compounds, and calcimimetics are widely used to slow the development and progression of CKD‐MBD complications.

PubMed Health Blog...

read all...